Developer docs
API playgroundTry for free, no card

Search company profiles

Kernal Biologics

Full company profile

uuid00005gr

Namestring
Kernal Biologics
Legal namestring
Kernal Biologics Inc.
Websiteurl
kernalbio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Kernal Biologics Inc. is a Cambridge, Massachusetts-based, development-stage private biotechnology company founded in 2018 that develops mRNA 2.0 therapeutics for cancer and autoimmune diseases. The company's core technology combines AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) to enable in vivo cell programming, eliminating the need for ex vivo manufacturing. The platform is anchored by kernaLM, a proprietary transformer-based large language model that predicts mRNA stability and translation efficiency, and supports two preclinical programs: KR-402, an in vivo CAR-T program for hematological malignancies and autoimmune disorders that achieves >90% in vivo delivery efficiency with T-cell-targeted LNPs, and KR-335, a solid-tumor program showing a 100x therapeutic index in preclinical models. Technology differentiators include two proprietary mRNA encryption designs that limit translation to cancer cells, extrahepatic LNP delivery that evades default liver accumulation, and an ML pipeline that mines clinical translatome datasets to identify cell-type-specific translation motifs.

The company's business model rests on two non-mutually-exclusive pillars: advancing its proprietary oncology and autoimmune pipeline toward clinical trials and IND filing, and licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharmaceutical and biotech partners for non-oncology applications. Kernal has secured strategic commercial validation through the Lilly Gateway Labs partnership (October 2025), technology ecosystem support via the NVIDIA Inception Program (August 2025), and up to $48 million in non-dilutive funding from ARPA-H (October 2025) for the KR-402 program. Total disclosed funding is approximately $81.5M from Hummingbird Ventures (lead), Amgen Ventures, Amino Collective, Civilization Ventures, Gaingels, HBM Genomics, HOF Capital, Y Combinator, and NASA. As of 2025, the company had 11-50 employees, no commercialized products, and no disclosed revenue.

Short descriptiontext

Kernal Biologics is a Cambridge, MA-based preclinical biotechnology company developing mRNA 2.0 therapeutics that combine AI-designed selective mRNA with antibody-decorated lipid nanoparticles to enable in vivo cell programming for cancer and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mRNA therapeutics, lipid nanoparticle delivery, in vivo CAR-T, cancer immunotherapy, autoimmune disease treatment
Industry2 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
mRNA Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing of non-oncology mRNA and LNP technology
TypeLicensing Royalties
Description

Kernal Bio licenses its proprietary non-immunogenic mRNA and extrahepatic lipid nanoparticle delivery technologies to global pharmaceutical and biotech companies for non-oncology applications such as infectious diseases, cardiovascular diseases, and metabolic disorders. This creates revenue to support internal oncology development programs.

kernalbio.com
2Clinical-stage therapeutic pipeline
TypeOne Time License
Description

The company is developing proprietary mRNA 2.0 therapeutics for cancer and autoimmune diseases (KR-335 for solid tumors, KR-402 for hematological malignancies). No commercial revenue yet as all programs remain in preclinical stage.

kernalbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1kernaLM™
Description

Proprietary large language model (LLM) developed by Kernal Biologics for predicting mRNA stability and translation efficiency, introduced in June 2025.

kernalbio.com
+1 more record
Core offering1 text field

Kernal Biologics engineers human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Its mRNA 2.0 platform combines AI-designed, cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) that deliver mRNA to specific tissues (tumors, spleen, bone marrow, T cells) and ensure selective translation only in target cells. The company is advancing preclinical programs KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting), while licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharma/biotech partners for non-oncology applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >90% in vivo delivery efficiency with T-cell-targeted LNPs (KR-402 program)
+3 more records
Product overview1 text field

Kernal Biologics is a biotech company that has developed an mRNA 2.0 Platform combining AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) for in vivo cell programming. The platform is anchored by kernaLM™, their proprietary large language model for mRNA design, and is supported by two clinical programs: KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting). The technology enables precise delivery of mRNA to specific cell types while ensuring selective translation only in target cells, eliminating off-target effects.

Product and service7 records
1mRNA 2.0 Platform
CategoryTherapeutics Platform
Description

Core technology platform combining AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) for precise in vivo cell programming. Enables targeted delivery to specific tissues and cells (tumors, spleen, bone marrow, T cells) while ensuring selective translation in target cells, minimizing off-target effects. Foundation for all Kernal Bio pipeline programs and licensing activities.

2kernaLM™
CategoryAI/Computational Drug Design
Description

Proprietary large language model (LLM) for mRNA design that predicts mRNA stability and translation efficiency. Built on transformer-based architecture, it processes genetic sequences, structural patterns, folding dynamics and multi-dimensional translatome data to computationally design selectively translated mRNA sequences for therapeutic applications.

3KR-402
CategoryCell Therapy Program
Description

In vivo CAR-T cell programming program targeting hematological malignancies (leukemia, lymphoma) and autoimmune disorders (multiple sclerosis, lupus). Uses T-cell-targeted antibody-decorated LNPs to deliver CAR mRNA for in situ CAR T programming without ex vivo manufacturing, achieving >90% in vivo delivery efficiency and effective B-cell depletion in preclinical models.

4KR-335
CategoryImmuno-Oncology Program
Description

Solid tumor targeting program for cancers resistant to standard immunotherapies, including bladder cancer, Merkel cell carcinoma, gastric cancer, ovarian cancer, triple-negative breast cancer (TNBC), small cell lung carcinoma, cutaneous squamous cell carcinoma, and head and neck cancer. Shows 100x therapeutic index with strong efficacy and tolerability in preclinical models.

5T-cell-targeted LNPs
CategoryDrug Delivery Technology
Description

Proprietary antibody-decorated lipid nanoparticles engineered to target T cells specifically. Evades default liver accumulation and achieves >90% in vivo delivery efficiency to T cells for targeted mRNA delivery, enabling in situ CAR-T programming.

6Extrahepatic LNP Delivery Technology
CategoryDrug Delivery Technology / Licensed Platform
Description

Lipid nanoparticle delivery technology engineered to reach the right cells in the right tissue, overcoming the default liver accumulation typical of conventional LNPs. Reaches target sites including tumors, spleen, and bone marrow. Available for licensing to global pharma and biotech partners for non-oncology applications.

7Non-oncology mRNA and LNP Technology Licensing
CategoryTechnology Licensing
Description

Out-licensing of Kernal Bio's proprietary non-immunogenic mRNA and extrahepatic lipid nanoparticle delivery technologies to global pharmaceutical and biotech companies for non-oncology therapeutic applications (infectious diseases, cardiovascular diseases, metabolic disorders). Generates licensing revenue to fund internal oncology pipeline development.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-03
Description

Kernal Bio joined Lilly Gateway Labs in October 2025 to accelerate the development of in vivo cell therapies. Lilly Gateway Labs supports early-stage biotech companies with resources to advance their programs.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-26
Description

Kernal Bio joined the NVIDIA Inception Program in August 2025. This provides access to NVIDIA's AI tools (RAPIDS, BioNeMo), GPU infrastructure, cloud resources, training, workshops, and a global network of AI startups and industry leaders. NVIDIA's computational resources will accelerate development of Kernal Bio's AI-driven mRNA design, including the kernaLM LLM.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest pure-play mRNA therapeutics company with a broad pipeline spanning infectious disease, oncology, and rare disease. Directly comparable to Kernal as a developer of mRNA-LNP therapeutics, but with far deeper clinical pipeline, manufacturing scale, and capital base.

TypeBroad incumbent
Description

Global mRNA therapeutics leader with approved COVID vaccine and an expanding oncology pipeline including CAR-T programs (e.g., BNT211). Overlaps directly with Kernal on mRNA-LNP delivery and immuno-oncology, with substantially greater clinical and manufacturing resources.

TypeEmerging player
Description

Synthetic biology company developing self-replicating and programmable mRNA therapeutics for oncology. Comparable to Kernal as an early-stage platform applying engineered mRNA logic to cancer, though Strand focuses on self-amplifying RNA rather than selective translation.

TypeEmerging player
Description

In vivo cell therapy company using LNP-delivered mRNA to engineer CAR-T cells inside the body, the same core mechanism as Kernal's KR-402. Most direct strategic comparator in the in vivo CAR-T space.

TypeEmerging player
Description

Developer of in vivo CAR-T and related cell therapies using LNP and viral delivery platforms. Comparable to Kernal in pursuing in vivo reprogramming of immune cells, with overlapping hematological malignancy and autoimmune targets.

TypeEmerging player
Description

Flagship Pioneering-incubated RNA therapeutics company working on a broad RNA modality portfolio including mRNA, saRNA, and circular RNA. Comparable to Kernal as an AI-enabled, platform-based RNA therapeutics developer.

7Laronde (now part of Sail Biomedicines)
TypeEmerging player
Description

Pioneer of engineered circular RNA (eRNA) for therapeutic protein expression. Comparable to Kernal as an emerging RNA therapeutics platform pursuing durable, programmable protein expression in vivo, though using a different RNA modality.

TypeEmerging player
Description

Developer of RNA editing therapeutics targeting neurological and retinal diseases. Comparable to Kernal as an RNA-based therapeutic platform pursuing in vivo editing of disease-causing transcripts.

TypeEmerging player
Description

Clinical-stage base editing company developing in vivo gene editing therapeutics using LNP delivery. Comparable to Kernal in pursuing targeted, in vivo nucleic acid delivery to specific tissues, though Beam edits DNA rather than expressing therapeutic proteins via mRNA.

TypeEmerging player
Description

Clinical-stage in vivo gene editing company using LNP delivery to edit genes in the liver for cardiovascular disease. Comparable to Kernal in its focus on extrahepatic and liver-targeted LNP delivery, though Verve edits genomic DNA rather than delivering therapeutic mRNA.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kernal Biologics

mRNA Therapeuticskernalbio.com

Kernal Biologics is a Cambridge, MA-based preclinical biotechnology company developing mRNA 2.0 therapeutics that combine AI-designed selective mRNA with antibody-decorated lipid nanoparticles to enable in vivo cell programming for cancer and autoimmune diseases.

What Kernal Biologics does

Kernal Biologics Inc. is a Cambridge, Massachusetts-based, development-stage private biotechnology company founded in 2018 that develops mRNA 2.0 therapeutics for cancer and autoimmune diseases. The company's core technology combines AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) to enable in vivo cell programming, eliminating the need for ex vivo manufacturing. The platform is anchored by kernaLM, a proprietary transformer-based large language model that predicts mRNA stability and translation efficiency, and supports two preclinical programs: KR-402, an in vivo CAR-T program for hematological malignancies and autoimmune disorders that achieves >90% in vivo delivery efficiency with T-cell-targeted LNPs, and KR-335, a solid-tumor program showing a 100x therapeutic index in preclinical models. Technology differentiators include two proprietary mRNA encryption designs that limit translation to cancer cells, extrahepatic LNP delivery that evades default liver accumulation, and an ML pipeline that mines clinical translatome datasets to identify cell-type-specific translation motifs.

The company's business model rests on two non-mutually-exclusive pillars: advancing its proprietary oncology and autoimmune pipeline toward clinical trials and IND filing, and licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharmaceutical and biotech partners for non-oncology applications. Kernal has secured strategic commercial validation through the Lilly Gateway Labs partnership (October 2025), technology ecosystem support via the NVIDIA Inception Program (August 2025), and up to $48 million in non-dilutive funding from ARPA-H (October 2025) for the KR-402 program. Total disclosed funding is approximately $81.5M from Hummingbird Ventures (lead), Amgen Ventures, Amino Collective, Civilization Ventures, Gaingels, HBM Genomics, HOF Capital, Y Combinator, and NASA. As of 2025, the company had 11-50 employees, no commercialized products, and no disclosed revenue.

Kernal Biologics firmographics

Firmographics
Name
Kernal Biologics
Legal name
Kernal Biologics Inc.
Website
https://kernalbio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Kernal Biologics is a Cambridge, MA-based preclinical biotechnology company developing mRNA 2.0 therapeutics that combine AI-designed selective mRNA with antibody-decorated lipid nanoparticles to enable in vivo cell programming for cancer and autoimmune diseases.
Ownership category
akta.pro rank

Kernal Biologics industry classification

Industry
Product category
mRNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • MRNA therapeutics
  • Lipid nanoparticle delivery
  • In vivo CAR-T
  • Cancer immunotherapy
  • Autoimmune disease treatment

Where Kernal Biologics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kernal Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Licensing of non-oncology mRNA and LNP technology: Kernal Bio licenses its proprietary non-immunogenic mRNA and extrahepatic lipid nanoparticle delivery technologies to global pharmaceutical and biotech companies for non-oncology applications such as infectious diseases, cardiovascular diseases, and metabolic disorders. This creates revenue to support internal oncology development programs.
  2. Clinical-stage therapeutic pipeline: The company is developing proprietary mRNA 2.0 therapeutics for cancer and autoimmune diseases (KR-335 for solid tumors, KR-402 for hematological malignancies). No commercial revenue yet as all programs remain in preclinical stage.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Kernal Biologics product offering

Product offering

Core offering

Kernal Biologics engineers human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Its mRNA 2.0 platform combines AI-designed, cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) that deliver mRNA to specific tissues (tumors, spleen, bone marrow, T cells) and ensure selective translation only in target cells. The company is advancing preclinical programs KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting), while licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharma/biotech partners for non-oncology applications.

Product overview

Kernal Biologics is a biotech company that has developed an mRNA 2.0 Platform combining AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) for in vivo cell programming. The platform is anchored by kernaLM™, their proprietary large language model for mRNA design, and is supported by two clinical programs: KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting). The technology enables precise delivery of mRNA to specific cell types while ensuring selective translation only in target cells, eliminating off-target effects.

Differentiator

Problem solved

Functional benefit

Brands

  • kernaLM™: Proprietary large language model (LLM) developed by Kernal Biologics for predicting mRNA stability and translation efficiency, introduced in June 2025.
  • mRNA 2.0

Products and services

  • mRNA 2.0 Platform Core technology platform combining AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) for precise in vivo cell programming. Enables targeted delivery to specific tissues and cells (tumors, spleen, bone marrow, T cells) while ensuring selective translation in target cells, minimizing off-target effects. Foundation for all Kernal Bio pipeline programs and licensing activities.
  • kernaLM™ Proprietary large language model (LLM) for mRNA design that predicts mRNA stability and translation efficiency. Built on transformer-based architecture, it processes genetic sequences, structural patterns, folding dynamics and multi-dimensional translatome data to computationally design selectively translated mRNA sequences for therapeutic applications.
  • KR-402 In vivo CAR-T cell programming program targeting hematological malignancies (leukemia, lymphoma) and autoimmune disorders (multiple sclerosis, lupus). Uses T-cell-targeted antibody-decorated LNPs to deliver CAR mRNA for in situ CAR T programming without ex vivo manufacturing, achieving >90% in vivo delivery efficiency and effective B-cell depletion in preclinical models.
  • KR-335 Solid tumor targeting program for cancers resistant to standard immunotherapies, including bladder cancer, Merkel cell carcinoma, gastric cancer, ovarian cancer, triple-negative breast cancer (TNBC), small cell lung carcinoma, cutaneous squamous cell carcinoma, and head and neck cancer. Shows 100x therapeutic index with strong efficacy and tolerability in preclinical models.
  • T-cell-targeted LNPs Proprietary antibody-decorated lipid nanoparticles engineered to target T cells specifically. Evades default liver accumulation and achieves >90% in vivo delivery efficiency to T cells for targeted mRNA delivery, enabling in situ CAR-T programming.
  • Extrahepatic LNP Delivery Technology Lipid nanoparticle delivery technology engineered to reach the right cells in the right tissue, overcoming the default liver accumulation typical of conventional LNPs. Reaches target sites including tumors, spleen, and bone marrow. Available for licensing to global pharma and biotech partners for non-oncology applications.
  • Non-oncology mRNA and LNP Technology Licensing Out-licensing of Kernal Bio's proprietary non-immunogenic mRNA and extrahepatic lipid nanoparticle delivery technologies to global pharmaceutical and biotech companies for non-oncology therapeutic applications (infectious diseases, cardiovascular diseases, metabolic disorders). Generates licensing revenue to fund internal oncology pipeline development.

Quantifiable outcome

  • >90% in vivo delivery efficiency with T-cell-targeted LNPs (KR-402 program)
  • +3 more outcomes

Companies that use Kernal Biologics

Customer profile

Segments3 records

Ideal customer profiles3 records

Kernal Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Kernal Biologics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Lilly Gateway LabscoreStrategic or Co-development Partner · 3 October 2025Kernal Bio joined Lilly Gateway Labs in October 2025 to accelerate the development of in vivo cell therapies. Lilly Gateway Labs supports early-stage biotech companies with resources to advance their programs.
  • NVIDIAcoreTechnology or Integration · 26 August 2025Kernal Bio joined the NVIDIA Inception Program in August 2025. This provides access to NVIDIA's AI tools (RAPIDS, BioNeMo), GPU infrastructure, cloud resources, training, workshops, and a global network of AI startups and industry leaders. NVIDIA's computational resources will accelerate development of Kernal Bio's AI-driven mRNA design, including the kernaLM LLM.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Kernal Biologics competitors and assessment

Company assessment

Broad incumbents

  • Moderna: Largest pure-play mRNA therapeutics company with a broad pipeline spanning infectious disease, oncology, and rare disease. Directly comparable to Kernal as a developer of mRNA-LNP therapeutics, but with far deeper clinical pipeline, manufacturing scale, and capital base.
  • BioNTech: Global mRNA therapeutics leader with approved COVID vaccine and an expanding oncology pipeline including CAR-T programs (e.g., BNT211). Overlaps directly with Kernal on mRNA-LNP delivery and immuno-oncology, with substantially greater clinical and manufacturing resources.

Emerging players

  • Strand Therapeutics: Synthetic biology company developing self-replicating and programmable mRNA therapeutics for oncology. Comparable to Kernal as an early-stage platform applying engineered mRNA logic to cancer, though Strand focuses on self-amplifying RNA rather than selective translation.
  • Capstan Therapeutics: In vivo cell therapy company using LNP-delivered mRNA to engineer CAR-T cells inside the body, the same core mechanism as Kernal's KR-402. Most direct strategic comparator in the in vivo CAR-T space.
  • Umoja Biopharma: Developer of in vivo CAR-T and related cell therapies using LNP and viral delivery platforms. Comparable to Kernal in pursuing in vivo reprogramming of immune cells, with overlapping hematological malignancy and autoimmune targets.
  • Orbital Therapeutics: Flagship Pioneering-incubated RNA therapeutics company working on a broad RNA modality portfolio including mRNA, saRNA, and circular RNA. Comparable to Kernal as an AI-enabled, platform-based RNA therapeutics developer.
  • Laronde (now part of Sail Biomedicines): Pioneer of engineered circular RNA (eRNA) for therapeutic protein expression. Comparable to Kernal as an emerging RNA therapeutics platform pursuing durable, programmable protein expression in vivo, though using a different RNA modality.
  • Ascidian Therapeutics: Developer of RNA editing therapeutics targeting neurological and retinal diseases. Comparable to Kernal as an RNA-based therapeutic platform pursuing in vivo editing of disease-causing transcripts.
  • Beam Therapeutics: Clinical-stage base editing company developing in vivo gene editing therapeutics using LNP delivery. Comparable to Kernal in pursuing targeted, in vivo nucleic acid delivery to specific tissues, though Beam edits DNA rather than expressing therapeutic proteins via mRNA.
  • Verve Therapeutics: Clinical-stage in vivo gene editing company using LNP delivery to edit genes in the liver for cardiovascular disease. Comparable to Kernal in its focus on extrahepatic and liver-targeted LNP delivery, though Verve edits genomic DNA rather than delivering therapeutic mRNA.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Kernal Biologics social profiles

Digital presence

Kernal Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kernal Biologics leadership team

Management profile

Number of profiles

Profiles17 records

Kernal Biologics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kernal Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kernal Biologics

What does Kernal Biologics do?

Kernal Biologics engineers human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Its mRNA 2.0 platform combines AI-designed, cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) that deliver mRNA to specific tissues (tumors, spleen, bone marrow, T cells) and ensure selective translation only in target cells. The company is advancing preclinical programs KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting), while licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharma/biotech partners for non-oncology applications.

Is Kernal Biologics a public or private company?

Kernal Biologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kernal Biologics founded?

Kernal Biologics was founded in 2018. It employs 11 to 50 people.

Where is Kernal Biologics based?

Kernal Biologics is headquartered in Cambridge, United States, in the North America region.

How does Kernal Biologics make money?

Two revenue lines are on record. Licensing of non-oncology mRNA and LNP technology is the primary driver. The others are clinical-stage therapeutic pipeline.

Who are Kernal Biologics's main competitors?

Broad incumbents on record are Moderna and BioNTech. Emerging players are Strand Therapeutics, Capstan Therapeutics, Umoja Biopharma, Orbital Therapeutics, Laronde (now part of Sail Biomedicines), Ascidian Therapeutics, Beam Therapeutics and Verve Therapeutics.

Does Kernal Biologics have an API?

No public API is recorded for Kernal Biologics.

What industry is Kernal Biologics in?

Kernal Biologics's product category is mRNA Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup ResearcherKernal Bio Secures IFLI Investment for KR-402Kernal Bio received a strategic investment from the Institute for Follicular Lymphoma Innovation to advance KR-402, an mRNA-based CAR-T candidate. The investment follows an ARPA-H award of up to US$48 million and adds support from NVIDIA, Microsoft, and Eli Lilly. The company is working to bring KR-402 to the clinic.FinSMEsKernal Bio Receives Investment From IFLIKernal Bio, a Cambridge, MA-based mRNA and lipid nanoparticle platform company, received an undisclosed investment from the Institute for Follicular Lymphoma Innovation (IFLI). The funds will accelerate development of KR-402, its mRNA-encoded CAR-T candidate for B-cell malignancies and autoimmune diseases.Dealroom.coKernal Bio adds IFLI backing and two hires to push in vivo CAR-T toward clinic | Dealroom NewsKernal Bio secured a strategic investment from IFLI and hired Kirsten Kester and Sieun K. Barnes to advance its in vivo CAR-T candidate KR-402. The funding supports the preclinical program, which aims to generate CAR-T cells directly in the body. The company did not disclose the investment amount.Business Wire BlogKernal Bio Announces Strategic Investment from IFLI and Leadership AppointmentsKernal Bio announced a strategic partnership with IFLI, including an investment to accelerate KR-402, its in vivo CAR-T candidate for follicular lymphoma and autoimmune diseases. The investment builds on a $48 million ARPA-H award and support from NVIDIA, Microsoft, and Eli Lilly. The company also appointed new leadership and board members.Stock TitanKernal Bio receives IFLI investment for KR-402Kernal Bio announced a strategic partnership with IFLI to accelerate development of KR-402, an in vivo CAR-T candidate for follicular lymphoma. The investment complements up to $48 million in non-dilutive funding from ARPA-H. The company also appointed new leadership and expanded its board.BioSpaceKernal Biologics to Showcase mRNA 2.0 Platform and T-Cell-Targeted LNPs for In Situ CAR T Programming at ASGCT 2026Kernal Biologics, Inc. announced it will showcase its new mRNA 2.0 platform and in situ CAR T programming with targeted lipid nanoparticles (LNPs) at the ASGCT Annual Meeting in Boston from May 11-15, 2026. The data presented indicate a significant increase in selectivity and effectiveness of the therapy in mouse models, which has implications for advancing CAR T therapies for more patients. Kernal Bio aims to make in vivo CAR T safe and scalable for broader clinical use.Business Wire BlogKernal Biologics to Showcase mRNA 2.0 Platform and T-Cell-Targeted LNPs for In Situ CAR T Programming at ASGCT 2026Kernal Biologics will present data on its mRNA 2.0 platform and T-cell-targeted LNPs at ASGCT 2026 in Boston. The data show up to 40-fold cell-selective translation in vitro and 10-fold oncoselective translation in mouse models, with rapid B-cell depletion in a single IV dose.FierceBiotechUS government earmarks up to $48M for development of Kernal's mRNA CAR-TThe U.S. government awarded Kernal Bio and three sub-awardees up to $48 million to advance its in vivo mRNA-encoded CAR T-cell program. The funding, from ARPA-H's EMBODY program, will support clinical development in multiple sclerosis and B-cell malignancies. The biotech aims to create less expensive in vivo CAR T-cell therapies for hematological cancers and autoimmune diseases.Business Wire BlogKernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune DiseaseKernal Biologics, Inc., a Boston-based TechBio company, has been awarded up to $48 million in funding by the Advanced Research Projects Agency for Health (ARPA-H) through its EMBODY program to advance its in vivo CAR T-cell therapy program. The funds will support clinical development of KR-402, targeting multiple sclerosis and B-cell malignancies, with collaboration from Stanford University School of Medicine, Dana-Farber Cancer Institute, and The Jackson Laboratory. The company claims its mRNA 2.0 platform has the potential to reduce manufacturing costs for CAR T-cell therapies by as much as 100-fold compared to traditional ex vivo approaches.PR NewswireKernal Biologics to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingKernal Biologics announced it is presenting preclinical data on its onco-selective mRNA LNP therapeutic KR-336 at the Society for Immunotherapy of Cancer 2023 Annual Meeting in San Diego on November 3, 2023. The data demonstrates that systemically administered KR-336 achieved tumor regression and improved overall survival as monotherapy in preclinical tumor models, supporting the feasibility of tumor-localized immunomodulation through systemic delivery. This represents a novel approach for treating patients with immunosuppressive tumors that may be resistant to checkpoint inhibitors.